Top 10 Pharma Drug Discovery Delivery Raises and Investors in the U.S. – January 1st – March 31st, 2026
Several interesting transactions closed in the Pharma Drug Discovery Delivery sector over the past quarter. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.
PE Growth/Expansion
- SHINE Technologies, fusion-based technology solutions that produce neutron sources for industrial imaging applications, and nuclear waste recycling, received $240 million of development capital.
PIPE
- LB Pharmaceuticals, a biopharmaceutical company that develops novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases, received $100 million of development capital.
- Mirum Pharmaceuticals, a biopharmaceutical company that develops and commercializes therapies for rare and orphan diseases, received $200 million of development capital.
Later Stage VC
- Altesa BioSciences, antiviral medicines for the treatment of respiratory infections and global viral threats, raised $75 million through a combination of Series B and Series B-1 venture funding in a deal led by Forbion.
- BreezeBio, curative therapies for current gene therapy delivery challenges, raised $60 million through a combination of debt, Series B and Series B-1 venture funding in a deal led by DSC Investment and Yuanta Investment.
- Earendil Labs, AI scientific computing platform for biotechnology firms, pharmaceutical companies, and research institutions, raised $787 million of Series C venture funding from Dimension Capital Management, 21Vita and DST Global.
Grant
- EpiFrontier Therapeutics, differentiated epigenetic modulator that safely and robustly increases fetal haemoglobin to treat sickle cell disease and other hemoglobinopathies, received $32 million of grant funding from Japan Agency for Medical Research and Developments.
- Kenai Therapeutics, induced pluripotent stem cell-based cell therapy platform that develops disease-modifying treatments for Parkinson’s disease and other central nervous system conditions, received $8 million of grant funding from California Institute for Regenerative Medicine.
Seed Round
- GelMEDIX, light-activated biomaterial platform that brings innovation in ocular and regenerative therapies, raised $13.54 million through a combination of Seed-1 and Seed-2 funding in a deal led by Safar Partners.
- ParcelBio, programmable technology that delivers messenger ribonucleic acid to diverse cell types in the body, raised $13.18 million through a combination of Seed funding from ZAKA VC, North South Ventures and Lexi Ventures.
#castleplacement #capitalraising #privateequity #venturecapital #investment #pharma #drug #drugdiscovery #drugdelivery
Raheem Suleman
Managing Director
Over two decades of experience in capital markets across capital raising, FX, futures, and stocks. Expertise in both business and technical aspects of trading and relationship management. Valuable insights into Asian and Middle Eastern capital markets. Broad understanding of the financial markets, and the insurance and reinsurance sectors. Extensive experience in the hospitality industry, managing multiple properties with responsibilities ranging from capital raising to daily operations. Completed the executive education program in private equity at the Wharton School. B.S. in Economics and Finance from the University of Waterloo. FINRA Series 7 and 63 licensed.
- Email: rsuleman@castleplacement.com
- (C) (646) 852-8007
Raheem Suleman
Managing Director
Please contact me if you have any questions or would like to discuss your capital raise:
Email: rsuleman@castleplacement.com
(C) (646) 852-8007
Send us a message:
Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement® does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.
